Molecular docking-based interaction studies on imidazo[1,2-a] pyridine ethers and squaramides as anti-tubercular agents

References

• World Health Organization, Global tuberculosis report 2022 (2022). Available at https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022.
   Google Scholar
• M.I. Gröschel, F. Sayes, R. Simeone, L. Majlessi, and R. Brosch, ESX secretion systems: Mycobacterial evolution to counter host immunity, Nat. Rev. Microbiol. 14 (2016), pp. 677–691. doi:10.1038/nrmicro.2016.131.
   PubMed Web of Science ®Google Scholar
• Q. Chai, Y. Zhang, and C.H. Liu, Mycobacterium tuberculosis: An adaptable pathogen associated with multiple human diseases, Front. Cell. Infect. Microbiol. 8 (2018), pp. 1–15. doi:10.3389/fcimb.2018.00158.
   PubMed Web of Science ®Google Scholar
• M. Caws, G. Thwaites, S. Dunstan, T.R. Hawn, N.T. Lan, N.T. Thuong, K. Stepniewska, M.N. Huyen, N.D. Bang, T.H. Loc, S. Gagneux, D. van Soolingen, K. Kremer, M. van der Sande, P. Small, P.T. Anh, N.T. Chinh, H.T. Quy, N.T. Duyen, D.Q. Tho, N.T. Hieu, E. Torok, T.T. Hien, N.H. Dung, N.T. Nhu, P.M. Duy, N. van Vinh Chau, and J. Farrar, The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis, PLoS Pathog. 4 (2008), pp. e1000034. doi:10.1371/journal.ppat.1000034.
   PubMed Web of Science ®Google Scholar
• H. Esmail, C.E. Barry III, D.B. Young, and R.J. Wilkinson, The ongoing challenge of latent tuberculosis, Philos. Trans. R. Soc. Lond. B Biol. Sci. 369 (2014), pp. 20130437. doi:10.1098/rstb.2013.0437.
   PubMed Web of Science ®Google Scholar
• M.G. Moule and J.D. Cirillo, Mycobacterium tuberculosis dissemination plays a critical role in pathogenesis, Front. Cell. Infect. Microbiol. 10 (2020), pp. 1–12. doi:10.3389/fcimb.2020.00065.
   PubMed Web of Science ®Google Scholar
• M.A. Aziz, A. Wright, A. Laszlo, A. De Muynck, F. Portaels, A. Van Deun, C. Wells, P. Nunn, L. Blanc, and M. Raviglione, Epidemiology of antituberculosis drug resistance (the global project on anti-tuberculosis drug resistance surveillance): An updated analysis, Lancet 368 (2006), pp. 2142–2154. doi:10.1016/s0140-6736(06)69863-2.
   PubMed Web of Science ®Google Scholar
• K.J. Seung, S. Keshavjee, and M.L. Rich, Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis, Cold Spring Harb. Perspect. Med. 5 (2015), pp. a017863. doi:10.1101/cshperspect.a017863.
   PubMed Web of Science ®Google Scholar
• A.K. Saxena and A. Singh, Mycobacterial tuberculosis enzyme targets and their inhibitors, Curr. Top. Med. Chem. 19 (2019), pp. 337–355. doi:10.2174/1568026619666190219105722.
   PubMed Web of Science ®Google Scholar
• S. Ahmed, S. Nandi, and A.K. Saxena, An updated patent review on drugs for the treatment of tuberculosis (2018-present), Expert Opin. Ther. Pat. 32 (2022), pp. 243–260. doi:10.1080/13543776.2022.2012151.
   PubMed Web of Science ®Google Scholar
• S. Nandi, M. Saxena, and A.K. Saxena, Important targets and inhibitors of Mycobacterium tuberculosis, in Tuberculosis: Integrated Studies for a Complex Disease, N. Rezaei, ed., Springer International Publishing, Cham, 2023, pp. 429–457.
   Google Scholar
• K.K. Roy, S. Singh, S.K. Sharma, R. Srivastava, V. Chaturvedi, and A.K. Saxena, Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H37RV, Bioorg. Med. Chem. Lett. 21 (2011), pp.5589–5593. doi:10.1016/j.bmcl.2011.06.076.
   PubMed Web of Science ®Google Scholar
• A.K. Saxena, K.K. Roy, S. Singh, S.P. Vishnoi, A. Kumar, V.K. Kashyap, L. Kremer, R. Srivastava, and B.S. Srivastava, Identification and characterisation of small-molecule inhibitors of Rv3097c-encoded lipase (LipY) of Mycobacterium tuberculosis that selectively inhibit growth of bacilli in hypoxia, Int. J. Antimicrob. Agents 42 (2013), pp. 27–35. doi:10.1016/j.ijantimicag.2013.03.007.
   PubMed Web of Science ®Google Scholar
• S.R. Khan, S. Singh, K.K. Roy, M.S. Akhtar, A.K. Saxena, and M.Y. Krishnan, Biological evaluation of novel substituted chloroquinolines targeting mycobacterial ATP synthase, Int. J. Antimicrob. Agents 41 (2013), pp. 41–46. doi:10.1016/j.ijantimicag.2012.09.012.
   PubMed Web of Science ®Google Scholar
• S. Janardhan, L. John, M. Prasanthi, V. Poroikov, and G. Narahari Sastry, A QSAR and molecular modelling study towards new lead finding: Polypharmacological approach to Mycobacterium tuberculosis, SAR QSAR Environ. Res. 28 (2017), pp. 815–832. doi:10.1080/1062936X.2017.1398782.
   PubMed Web of Science ®Google Scholar
• S. Nandi, S. Ahmed, and A.K. Saxena, Combinatorial design and virtual screening of potent anti-tubercular fluoroquinolone and isothiazoloquinolone compounds utilizing QSAR and pharmacophore modelling, SAR QSAR Environ. Res. 29 (2018), pp. 151–170. doi:10.1080/1062936X.2017.1419375.
   PubMed Web of Science ®Google Scholar
• P. Kamsri, A. Punkvang, S. Hannongbua, K. Suttisintong, P. Kittakoop, J. Spencer, A.J. Mulholland, and P. Pungpo, In silico study directed towards identification of the key structural features of GyrB inhibitors targeting MTB DNA gyrase: HQSAR, CoMSIA and molecular dynamics simulations, SAR QSAR Environ. Res. 30 (2019), pp. 775–800. doi:10.1080/1062936X.2019.1658218.
   PubMed Web of Science ®Google Scholar
• H. Verma, S. Choudhary, M. Kumar, and O. Silakari, In silico guided design of non-covalent inhibitors of DprE1: Synthesis and biological evaluation, SAR QSAR Environ. Res. 32 (2021), pp. 333–352. doi:10.1080/1062936X.2021.1900390.
   PubMed Web of Science ®Google Scholar
• The Working Group for New TB Drugs, Clinical Pipeline (2023). Available at https://www.newtbdrugs.org/pipeline/clinical.
   Google Scholar
• S.P. Alexander, H.D. Andreas, T. Shen-Jie, C. Francesca, D. Manfred, C. Charoen, V. Irina, A. Koen, B. Nyasha, M. Tine De, H.-T. Myriam, L. Nacer, M. Paul, B. Ben Van, P.G.V.H. Rolf, and D. Brian, Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis, Eur. Respir. J. 47 (2016), pp. 564–574. doi:10.1183/13993003.00724-2015.
   PubMed Web of Science ®Google Scholar
• R. Mahajan, Bedaquiline: First FDA-approved tuberculosis drug in 40 years, Int. J. Appl. Basic Med. Res. 3 (2013), pp. 1–2. doi:10.4103/2229-516X.112228.
   PubMedGoogle Scholar
• S.-H. Wu, -H.-H. Chan, H.-C. Hsiao, and R. Jou, Primary bedaquiline resistance among cases of drug-resistant tuberculosis in Taiwan, Front. Microbiol. 12 (2021), pp. 1–10. doi:10.3389/fmicb.2021.754249.
   Google Scholar
• G. Degiacomi, J.C. Sammartino, V. Sinigiani, P. Marra, A. Urbani, and M.R. Pasca, In vitro study of bedaquiline resistance in Mycobacterium tuberculosis multi-drug resistant clinical isolates, Front. Microbiol. 11 (2020), pp. 1–8. doi:10.3389/fmicb.2020.559469.
   PubMedGoogle Scholar
• T.V.A. Nguyen, R.M. Anthony, A.-L. Bañuls, T.V.A. Nguyen, D.H. Vu, and J.-W.C. Alffenaar, Bedaquiline resistance: Its emergence, mechanism, and prevention, Clin. Infect. Dis. 66 (2017), pp. 1625–1630. doi:10.1093/cid/cix992.
   Web of Science ®Google Scholar
• N. Camus, M. James, B. Kayleen, M. Sashen, D. Lucy van, L. Keeren, W. Allison, D.G. Alison, B. Francois, S.P. Alexander, P. Nesri, O. Max, and Donnell, Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients, Eur. Respir. J. 55 (2020), pp. 1902383. doi:10.1183/13993003.02383-2019.
   PubMed Web of Science ®Google Scholar
• N.A. Ismail, S.V. Omar, H. Moultrie, Z. Bhyat, F. Conradie, M. Enwerem, H. Ferreira, J. Hughes, L. Joseph, Y. Kock, V. Letsaolo, G. Maartens, G. Meintjes, D. Ngcamu, N. Okozi, X. Padanilam, A. Reuter, R. Romero, S. Schaaf, J. te Riele, E. Variava, M. van der Meulen, F. Ismail, and N. Ndjeka, Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: A cross-sectional and longitudinal study, Lancet Infect. Dis. 22 (2022), pp. 496–506. doi:10.1016/S1473-3099(21)00470-9.
   PubMed Web of Science ®Google Scholar
• G.P. Mishra and J. Mulani, Implications of bedaquiline-resistant tuberculosis, Lancet Infect. Dis. 22 (2022), pp. 166. doi:10.1016/S1473-3099(22)00007-X.
   PubMedGoogle Scholar
• R. Girase, I. Ahmad, R. Pawara, and H. Patel, Optimizing cardio, hepato and phospholipidosis toxicity of the bedaquiline by chemoinformatics and molecular modelling approach, SAR QSAR Environ. Res. 33 (2022), pp. 215–235. doi:10.1080/1062936X.2022.2041724.
   PubMed Web of Science ®Google Scholar
• W. Yu and A.D. MacKerell, Computer-aided drug design methods, in Antibiotics: Methods and Protocols, P. Sass, ed., Springer, New York, NY, 2017, pp. 85–106.
   Google Scholar
• H.M. Baig, K. Ahmad, G. Rabbani, M. Danishuddin, and I. Choi, Computer aided drug design and its application to the development of potential drugs for neurodegenerative disorders, Curr. Neuropharmacol. 16 (2018), pp. 740–748. doi:10.2174/1570159X15666171016163510.
   PubMed Web of Science ®Google Scholar
• P. Prathipati, A. Dixit, and K.A. Saxena, Computer-aided drug design: Integration of structure-based and ligand-based approaches in drug design, Curr. Comput. Aided Drug. Des. 3 (2007), pp. 133–148. doi:10.2174/157340907780809516.
   Web of Science ®Google Scholar
• M. Batool, B. Ahmad, and S. Choi, A structure-based drug discovery paradigm, Int. J. Mol. Sci. 20 (2019), pp. 1–18. doi:10.3390/ijms20112783.
   Web of Science ®Google Scholar
• A.C. Anderson, The process of structure-based drug design, Chem. Biol. 10 (2003), pp. 787–797. doi:10.1016/j.chembiol.2003.09.002.
   PubMed Web of Science ®Google Scholar
• S.S. Bhunia, M. Saxena, and A.K. Saxena, Ligand- and structure-based virtual screening in drug discovery, in Biophysical and Computational Tools in Drug Discovery, A.K. Saxena, ed., Springer International Publishing, Cham, 2021, pp. 281–339.
   Google Scholar
• E. Lionta, G. Spyrou, D.K. Vassilatis, and Z. Cournia, Structure-based virtual screening for drug discovery: Principles, applications and recent advances, Curr. Top. Med. Chem. 14 (2014), pp. 1923–1938. doi:10.2174/1568026614666140929124445.
   PubMed Web of Science ®Google Scholar
• H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne, The protein data bank, Nucleic Acids Res. 28 (2000), pp. 235–242. doi:10.1093/nar/28.1.235.
   PubMed Web of Science ®Google Scholar
• A. Bortolato, M. Fanton, J.S. Mason, and S. Moro, Molecular docking methodologies, in Biomolecular Simulations: Methods and Protocols, L. Monticelli and E. Salonen, eds., Humana Press, Totowa, NJ, 2013, pp. 339–360.
   Google Scholar
• D.B. Kitchen, H. Decornez, J.R. Furr, and J. Bajorath, Docking and scoring in virtual screening for drug discovery: Methods and applications, Nat. Rev. Drug Discov. 3 (2004), pp. 935–949. doi:10.1038/nrd1549.
   PubMed Web of Science ®Google Scholar
• N.S. Pagadala, K. Syed, and J. Tuszynski, Software for molecular docking: A review, Biophys. Rev. 9 (2017), pp. 91–102. doi:10.1007/s12551-016-0247-1.
   PubMedGoogle Scholar
• R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, D.E. Shaw, P. Francis, and P.S. Shenkin, Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy, J. Med. Chem. 47 (2004), pp. 1739–1749. doi:10.1021/jm0306430.
   PubMed Web of Science ®Google Scholar
• E. Yuriev, M. Agostino, and P.A. Ramsland, Challenges and advances in computational docking: 2009 in review, J. Mol. Recognit. 24 (2011), pp. 149–164. doi:10.1002/jmr.1077.
   PubMed Web of Science ®Google Scholar
• J. Ren, Y. He, W. Chen, T. Chen, G. Wang, Z. Wang, Z. Xu, X. Luo, W. Zhu, H. Jiang, J. Shen, and Y. Xu, Thermodynamic and structural characterization of halogen bonding in protein–ligand interactions: A case study of PDE5 and its inhibitors, J. Med. Chem. 57 (2014), pp. 3588–3593. doi:10.1021/jm5002315.
   PubMed Web of Science ®Google Scholar
• Y. Yang, Z. Xu, Z. Zhang, Z. Yang, Y. Liu, J. Wang, T. Cai, S. Li, K. Chen, J. Shi, and W. Zhu, Like-charge guanidinium pairing between ligand and receptor: An unusual interaction for drug discovery and design? J. Phys. Chem. B 119 (2015), pp. 11988–11997. doi:10.1021/acs.jpcb.5b04130.
   PubMed Web of Science ®Google Scholar
• F. Spyrakis and C.N. Cavasotto, Open challenges in structure-based virtual screening: Receptor modeling, target flexibility consideration and active site water molecules description, Arch. Biochem. Biophys. 583 (2015), pp. 105–119. doi:10.1016/j.abb.2015.08.002.
   PubMed Web of Science ®Google Scholar
• J. Li, A. Fu, and L. Zhang, An overview of scoring functions used for protein–ligand interactions in molecular docking, Interdiscip. Sci. Comput. Life Sci. 11 (2019), pp. 320–328. doi:10.1007/s12539-019-00327-w.
   PubMed Web of Science ®Google Scholar
• S. Ahmed, A.E. Prabahar, and A.K. Saxena, Molecular docking-based interactions in QSAR studies on Mycobacterium tuberculosis ATP synthase inhibitors, SAR QSAR Environ. Res. 33 (2022), pp. 289–305. doi:10.1080/1062936X.2022.2066175.
   PubMed Web of Science ®Google Scholar
• S. Singh, K.K. Roy, S.R. Khan, V.K. Kashyap, A. Sharma, S. Jaiswal, S.K. Sharma, M.Y. Krishnan, V. Chaturvedi, J. Lal, S. Sinha, A. Dasgupta, R. Srivastava, and A.K. Saxena, Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis, Bioorg. Med. Chem. 23 (2015), pp. 742–752. doi:10.1016/j.bmc.2014.12.060.
   PubMed Web of Science ®Google Scholar
• S. Singh, S.R.K. K.K.Roy, V.K. Kashyap, S.K. Sharma, M.Y. Krishnan, V. Chaturvedi, S.K. Sinha, R. Shrivastava, and A.K. Saxena, N-(3-((diethylamino) methyl)-4-hydroxyphenyl)-n-(quinolin-4-yl) sulfonamides for the treatment of tuberculosis and process of preparation thereof, WO2013102936A1, 2013.
   Google Scholar
• S.S. Chaudhaery, K.K. Roy, N. Shakya, G. Saxena, S.R. Sammi, A. Nazir, C. Nath, and A.K. Saxena, Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: Pharmacophore-based virtual screening, synthesis, and pharmacology, J. Med. Chem. 53 (2010), pp. 6490–6505. doi:10.1021/jm100573q.
   PubMed Web of Science ®Google Scholar
• K.K. Roy, C.N. S.Tota, R. Shukla, and A.K. Saxena, Substituted 1, 2, 3, 4-tetrahydroquinolin-7-yl carbamates as acetylcholinesterase inhibitors for treatment of Alzheimer’s disease, US20130324573A1, 2012.
   Google Scholar
• S.S. Bhunia, A. Misra, I.A. Khan, S. Gaur, M. Jain, S. Singh, A. Saxena, T. Hohlfield, M. Dikshit, and A.K. Saxena, Novel glycoprotein VI antagonists as antithrombotics: Synthesis, biological evaluation, and molecular modeling studies on 2,3-disubstituted tetrahydropyrido (3,4-b)indoles, J. Med. Chem. 60 (2017), pp. 322–337. doi:10.1021/acs.jmedchem.6b01360.
   PubMed Web of Science ®Google Scholar
• S. Gaur, Z. Fatima, A. Dixit, Z. Ali, W.R. Surin, K. Kapoor, K. Bhutani, M.S. Ansari, M. Dikshit, and A.K. Saxena, 2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido(3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents, US20070287723A1, 2004.
   Google Scholar
• S.J. Tantry, S.D. Markad, V. Shinde, J. Bhat, G. Balakrishnan, A.K. Gupta, A. Ambady, A. Raichurkar, C. Kedari, S. Sharma, N.V. Mudugal, A. Narayan, C.N. Naveen Kumar, R. Nanduri, S. Bharath, J. Reddy, V. Panduga, K.R. Prabhakar, K. Kandaswamy, R. Saralaya, P. Kaur, N. Dinesh, S. Guptha, K. Rich, D. Murray, H. Plant, M. Preston, H. Ashton, D. Plant, J. Walsh, P. Alcock, K. Naylor, M. Collier, J. Whiteaker, R.E. McLaughlin, M. Mallya, M. Panda, S. Rudrapatna, V. Ramachandran, R. Shandil, V.K. Sambandamurthy, K. Mdluli, C.B. Cooper, H. Rubin, T. Yano, P. Iyer, S. Narayanan, S. Kavanagh, K. Mukherjee, V. Balasubramanian, V.P. Hosagrahara, S. Solapure, S. Ravishankar, and S.P. Hameed, Discovery of Imidazo[1,2- a]pyridine ethers and squaramides as selective and potent inhibitors of mycobacterial Adenosine Triphosphate (ATP) synthesis, J. Med. Chem. 60 (2017), pp. 1379–1399. doi:10.1021/acs.jmedchem.6b01358.
   PubMed Web of Science ®Google Scholar
• D. Kalia, A.K.K. S, G. Meena, K.P. Sethi, R. Sharma, P. Trivedi, S.R. Khan, A.S. Verma, S. Singh, S. Sharma, K.K. Roy, R. Kant, M.Y. Krishnan, B.N. Singh, S. Sinha, V. Chaturvedi, A.K. Saxena, and D.K. Dikshit, Synthesis and anti-tubercular activity of conformationally-constrained and bisquinoline analogs of TMC207, Med. Chem. Commun. 6 (2015), pp. 1554–1563. doi:10.1039/C5MD00131E.
   Google Scholar
• BIOVIA, Biovia Draw 19.1, Dassault Systemes, San Diego, 2019.
   Google Scholar
• LigPrep version 2.3. Schrödinger, LLC., NewYork, NY, 2009. Available at http://www.schrodinger.com.
   Google Scholar
• Schrödinger version 9.0. Schrödinger, LLC., NewYork, NY, 2009. Available at http://www.schrodinger.com.
   Google Scholar
• L. Preiss, J.D. Langer, Ö. Yildiz, L. Eckhardt-Strelau, J.E.G. Guillemont, A. Koul, and T. Meier, Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline, Sci. Adv. 1 (2015), pp. e1500106. doi:10.1126/sciadv.1500106.
   PubMed Web of Science ®Google Scholar
• Protein preparation wizard. Schrödinger, LLC., NewYork, NY, 2009. Available at http://www.schrodinger.com.
   Google Scholar
• Glide version 5.5. Schrödinger, LLC., NewYork, NY, 2009. Available at http://www.schrodinger.com.
   Google Scholar
• BIOVIA, Discovery Studio Visualizer 20.1.0, Dassault Systemes, San Diego, 2020.
   Google Scholar
• Minitab version 14. 2005. Available at http://www.minitab.com/en-US/products/minitab/default.aspx.
   Google Scholar
• J. Guillemont, C. Meyer, A. Poncelet, X. Bourdrez, and K. Andries, Diarylquinolines, synthesis pathways and quantitative structure–activity relationship studies leading to the discovery of TMC207, Future Med. Chem. 3 (2011), pp. 1345–1360. doi:10.4155/fmc.11.79.
   PubMed Web of Science ®Google Scholar
• S.A. Hollingsworth and R.O. Dror, Molecular dynamics simulation for all, Neuron 99 (2018), pp. 1129–1143. doi:10.1016/j.neuron.2018.08.011.
   PubMed Web of Science ®Google Scholar
• S. Bernèche and B. Roux, Energetics of ion conduction through the K+ channel, Nature 414 (2001), pp. 73–77. doi:10.1038/35102067.
   PubMed Web of Science ®Google Scholar
• J. Li, S.A. Shaikh, G. Enkavi, P.C. Wen, Z. Huang, and E. Tajkhorshid, Transient formation of water-conducting states in membrane transporters, Proc. Natl. Acad. Sci. USA 110 (2013), pp. 7696–7701. doi:10.1073/pnas.1218986110.
   PubMed Web of Science ®Google Scholar
• R.O. Dror, H.F. Green, C. Valant, D.W. Borhani, J.R. Valcourt, A.C. Pan, D.H. Arlow, M. Canals, J.R. Lane, R. Rahmani, J.B. Baell, P.M. Sexton, A. Christopoulos, and D.E. Shaw, Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs, Nature 503 (2013), pp. 295–299. doi:10.1038/nature12595.
   PubMed Web of Science ®Google Scholar
• D. Wacker, S. Wang, J.D. McCorvy, R.M. Betz, A.J. Venkatakrishnan, A. Levit, K. Lansu, Z.L. Schools, T. Che, D.E. Nichols, B.K. Shoichet, R.O. Dror, and B.L. Roth, Crystal structure of an LSD-bound human serotonin receptor, Cell 168 (2017), pp. 377–389.e12. doi:10.1016/j.cell.2016.12.033.
   PubMed Web of Science ®Google Scholar
• M. Vendruscolo and C.M. Dobson, Protein dynamics: Moore’s law in molecular biology, Curr. Biol. 21, 2 (2011), pp. R68–70. doi:10.1016/j.cub.2010.11.062.
   PubMed Web of Science ®Google Scholar
• K. Lindorff-Larsen, S. Piana, R.O. Dror, and D.E. Shaw, How fast-folding proteins fold, Science 334 (2011), pp. 517–520. doi:10.1126/science.1208351.
   PubMed Web of Science ®Google Scholar
• S. Piana, J.L. Klepeis, and D.E. Shaw, Assessing the accuracy of physical models used in protein-folding simulations: Quantitative evidence from long molecular dynamics simulations, Curr. Opin. Struct. Biol. 24 (2014), pp. 98–105. doi:10.1016/j.sbi.2013.12.006.
   PubMed Web of Science ®Google Scholar
• H.I. Ingólfsson, C.A. Lopez, J.J. Uusitalo, D.H. de Jong, S.M. Gopal, X. Periole, and S.J. Marrink, The power of coarse graining in biomolecular simulations, Wiley Interdiscip. Rev. Comput. Mol. Sci. 4 (2014), pp. 225–248. doi:10.1002/wcms.1169.
   PubMed Web of Science ®Google Scholar
• P.J. Bond, J. Holyoake, A. Ivetac, S. Khalid, and M.S. Sansom, Coarse-grained molecular dynamics simulations of membrane proteins and peptides, J. Struct. Biol. 157 (2007), pp. 593–605. doi:10.1016/j.jsb.2006.10.004.
   PubMed Web of Science ®Google Scholar
• G.A. Voth (ed.), Coarse-graining of Condensed Phase and Biomolecular Systems, CRC press, Boca Raton, 2008.
   Google Scholar
• M. Rueda, C. Ferrer-Costa, T. Meyer, A. Pérez, J. Camps, A. Hospital, J.L. Gelpí, and M. Orozco, A consensus view of protein dynamics, Proc. Natl. Acad. Sci. USA 104 (2007), pp. 796–801. doi:10.1073/pnas.0605534104.
   PubMed Web of Science ®Google Scholar
• M. Orozco, L. Orellana, A. Hospital, A.N. Naganathan, A. Emperador, O. Carrillo, and J.L. Gelpí, Coarse-grained representation of protein flexibility. Foundations, successes, and shortcomings, Adv. Protein Chem. Struct. Biol. 85 (2011), pp. 183–215. doi:10.1016/b978-0-12-386485-7.00005-3.
   PubMed Web of Science ®Google Scholar
• Sumera, F. Anwer, M. Waseem, A. Fatima, N. Malik, and A. Ali, Molecular docking and molecular dynamics studies reveal secretory proteins as novel targets of temozolomide in glioblastoma multiforme, Molecules 27 (2022), pp. 1–16. doi:10.3390/molecules27217198.
   Web of Science ®Google Scholar
• T. Julaton, A. Taclendo, G. Oyong, O. Rempillo, M.C. Galvez, and E. Vallar, In silico insights on the pro-inflammatory potential of polycyclic aromatic hydrocarbons and the prospective anti-inflammatory capacity of Andrographis paniculata phytocompounds, Int. J. Environ. Res. Public Health 19 (2022), pp. 1–31. doi:10.3390/ijerph19148588.
   Web of Science ®Google Scholar
• Y. Yuniwati, M.F.R. Syaban, S.G. Anoraga, and F.L. Sabila, Molecular docking approach of Bryophyllum pinnatum compounds as atherosclerosis therapy by targeting adenosine monophosphate-activated protein kinase and inducible nitric oxide synthase, Acta. Inform. Med. 30 (2022), pp. 91–95. doi:10.5455/aim.2022.30.91-95.
   PubMedGoogle Scholar
• M. Jamroz, A. Kolinski, and S. Kmiecik, CABS-flex: Server for fast simulation of protein structure fluctuations, Nucleic Acids Res. 41 (2013), pp. W427–31. doi:10.1093/nar/gkt332.
   PubMed Web of Science ®Google Scholar
• M. Jamroz, M. Orozco, A. Kolinski, and S. Kmiecik, Consistent view of protein fluctuations from all-atom molecular dynamics and coarse-grained dynamics with knowledge-based force-field, J. Chem. Theory Comput. 9 (2013), pp. 119–125. doi:10.1021/ct300854w.
   PubMed Web of Science ®Google Scholar